Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NeoGenomics, Inc. - Common Stock (NQ: NEO )

14.42 +0.51 (+3.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Target To $200? Here Are 5 Other Price Target Changes For Thursday
Raymond James raised the price target on Target Corporation (NYSE: TGT) from $190 to $200. However, Raymond James analyst Bobby Griffin maintained the stock with a Strong Buy. Target shares fell 0.1%... 
Via Benzinga
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Earnings Scheduled For August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. 
Via Benzinga
What 4 Analyst Ratings Have To Say About NeoGenomics
  NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
NeoGenomics: Q2 Earnings Insights
  NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
NeoGenomics Reports Revenue of $125 Million in the Second Quarter
Via ACCESSWIRE
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
Via ACCESSWIRE
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022
Upgrades 
Via Benzinga
Turnaround For This Cancer Genetics Testing Firm Could Take Years, Analyst Says While Downgrading Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
Upgrades 
Via Benzinga
NeoGenomics: Q2 Earnings Insights
  NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
NeoGenomics Announces Chief Executive Officer Appointment
Via ACCESSWIRE
NeoGenomics Announces Chief Executive Officer Appointment
Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms... 
From NeoGenomics, Inc.
Via AccessWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
Analyst Ratings for NeoGenomics
Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
Via Benzinga
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D 
From NeoGenomics, Inc.
Via AccessWire
NASDAQ:NEO Investor Alert: Investigation over Possible Wrongdoing at NeoGenomics, Inc.
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Certain directors of NeoGenomics, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics Appoints Lynn Tetrault Interim CEO
FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services,... 
From NeoGenomics, Inc.
Via AccessWire
Earnings Scheduled For May 13, 2022
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.